This population cohort has a sample size of 8.592 subjects, enriched for subjects with higher albuminuria. The study started in 1997 in the city of Groningen, the Netherlands with a baseline screening and has 5 follow-up screening rounds with 3 to 4 year intervals. Participants are extremely well pheno- and genotyped.
Male and female residents of the city Groningen (the Netherlands) between the age of 27 and 75 years.
Please visit the UMCG Research Data Catalogue for more detailed information on our data and samples.
Collected data include among others:
Although the PREVEND-cohort does not collect any new data, researchers are now still using the collected data. In total, PREVEND has led to more than 400 publications and dozens of PhD theses. These publications have been cited approximately 16.000 times. The success of PREVEND was also cause for starting Lifelines, the Niercheck and the Check@Home consortium. Moreover, the interest that this study generated for albuminuria as important risk marker for cardiovascular and renal disease led to the new KDIGO definition and classification of chronic kidney disease, that now has also been adopted by the World Health Organization and the International Classification of Diseases.
University Medical Center Groningen (UMCG)
PREVEND
PO Box 30.001
9700 RB Groningen
The Netherlands
Visiting address
University Medical Center Groningen (UMCG)
Antonius Deusinglaan 1
9713 AV Groningen
